Duration of Postvaccination Neutralizing Antibodies to SARS-CoV-2 and Medication Effects: Results from the Safety and Immunogenicity of COVID-19 Vaccination in Systemic Immune-Mediated Inflammatory Diseases Cohort Study

被引:0
|
作者
Habib, Rami [1 ]
Dayam, Roya M. [2 ]
Hitchon, Carol [3 ]
Chandran, Vinod [4 ,5 ]
Fortin, Paul R. [6 ]
Boire, Gilles [7 ]
Bowdish, Dawn M. E. [8 ]
Gingras, Anne-Claude [2 ]
Flamand, Louis [6 ,9 ]
Larche, Maggie J. [8 ]
Colmegna, Ines [1 ]
Lukusa, Luck [1 ]
Lee, Jennifer L. F. [1 ]
Pereira, Daniel [10 ]
Bernstein, Charles N. [3 ]
Lalonde, Nadine [11 ]
Turnbull, Elizabeth [1 ]
Bernatsky, Sasha [1 ]
机构
[1] McGill Univ, Montreal, PQ, Canada
[2] Mt Sinai Hosp, Sinai Hlth, Toronto, ON, Canada
[3] Univ Manitoba, Winnipeg, MB, Canada
[4] Univ Hlth Network, Schroeder Arthrit Inst, Krembil Res Inst, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Univ Laval, Ctr Hosp Univ CHU Quebec, Res Ctr, Quebec City, PQ, Canada
[7] Univ Sherbrooke, Sherbrooke, PQ, Canada
[8] McMaster Univ, Hamilton, ON, Canada
[9] Univ Laval, Quebec City, PQ, Canada
[10] Univ Hlth Network, Schroeder Arthrit Inst, Krembil Res Inst, Toronto, ON, Canada
[11] Canadian Arthrit Patient Alliance, Toronto, ON, Canada
关键词
D O I
10.1002/acr2.11697
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveIn the face of the ongoing circulation of SARS-CoV-2, the durability of neutralization post-COVID-19 vaccination in immune-mediated inflammatory disease (IMID) is a key issue, as are the effects of medications.MethodsAdults (n = 112) with inflammatory bowel disease, psoriasis/psoriatic arthritis, rheumatoid arthritis, spondylarthritis, and systemic lupus were recruited from participating Canadian medical centers from 2021 to 2023. We focused on log-transformed neutralization (lentivirus methods) as a continuous outcome, with separate models for wild-type and Omicron strains BA.1 and BA.5.ResultsCompared with 30 to 120 days postvaccination, subsequent periods were associated with greater neutralization in unadjusted models for wild-type, BA.1, and BA.5 strains and against the BA.1 strain in adjusted models. Rituximab was associated with lower neutralization for the BA.1 strain in adjusted models, with a similar trend for BA.5. In methotrexate users, there were trends for less neutralization of BA.1 and BA.5 in all unadjusted models, whereas in adjusted models, there was significantly lower neutralization only for the wild type. Three or more doses and Omicron-specific vaccines were both independently associated with better neutralization ability for all three strains. A COVID-19 infection within six months before sampling was associated with higher neutralization of wild type and BA.1 in adjusted analyses. Anti-tumor necrosis factor agents were associated with lower neutralization ability for BA.5 in adjusted analyses.ConclusionNeutralization responses in immunosuppressed individuals with IMID were durable over time and were augmented by more than three doses and Omicron-specific vaccines. Less neutralization was seen with certain medications. Our work clarifies the joint effects of vaccine history, infection, and medications on COVID-19 immunity.
引用
下载
收藏
页数:6
相关论文
共 50 条
  • [41] Vaccination of COVID-19 convalescent plasma donors increases binding and neutralizing antibodies against SARS-CoV-2 variants
    Di Germanio, Clara
    Simmons, Graham
    Thorbrogger, Chloe
    Martinelli, Rachel
    Stone, Mars
    Gniadek, Thomas
    Busch, Michael P.
    TRANSFUSION, 2022, 62 (03) : 563 - 569
  • [42] Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study
    Belleudi, Valeria
    Rosa, Alessandro C.
    Poggi, Francesca R.
    Armuzzi, Alessandro
    Nicastri, Emanuele
    Goletti, Delia
    Diamanti, Andrea Picchianti
    Davoli, Marina
    Agabiti, Nera
    Addis, Antonio
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (11)
  • [43] The persistence of SARS-CoV-2 neutralizing antibodies after COVID-19: A one-year observation. Is a SARS-CoV-2 vaccination booster dose necessary?
    Tworek, Adam
    Jaron, Krzysztof
    Cicha, Malgorzata
    Rydzewski, Andrzej
    Wierzba, Waldemar
    Zaczynski, Arturza
    Krol, Zbigniew
    Rydzewska, Grazyna
    CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2023, 48 (02) : 92 - 96
  • [44] SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases
    Simon, David
    Tascilar, Koray
    Fagni, Filippo
    Kroenke, Gerhard
    Kleyer, Arnd
    Meder, Christine
    Atreya, Raja
    Leppkes, Moritz
    Kremer, Andreas E.
    Ramming, Andreas
    Pachowsky, Milena L.
    Schuch, Florian
    Ronneberger, Monika
    Kleinert, Stefan
    Hueber, Axel J.
    Manger, Karin
    Manger, Bernhard
    Berking, Carola
    Sticherling, Michael
    Neurath, Markus F.
    Schett, Georg
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (10) : 1312 - 1316
  • [45] Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
    Konig, Marton
    Torgauten, Hilde Marie
    Tran, The Trung
    Holmoy, Trygve
    Vaage, John Torgils
    Lund-Johansen, Fridtjof
    Nygaard, Gro Owren
    JAMA NEUROLOGY, 2022, 79 (03) : 307 - 309
  • [46] Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort
    Rockstroh, Alexandra
    Wolf, Johannes
    Fertey, Jasmin
    Kalbitz, Sven
    Schroth, Stefanie
    Luebbert, Christoph
    Ulbert, Sebastian
    Borte, Stephan
    EMERGING MICROBES & INFECTIONS, 2021, 10 (01) : 774 - 781
  • [47] Immune-mediated neurological syndrome in SARS-CoV-2 infection: a review of literature on autoimmune encephalitis in COVID-19
    Alvin Oliver Payus
    Mohammad Saffree Jeffree
    May Honey Ohn
    Hui Jan Tan
    Azliza Ibrahim
    Yuen Kang Chia
    Azman Ali Raymond
    Neurological Sciences, 2022, 43 : 1533 - 1547
  • [48] Immune-mediated neurological syndrome in SARS-CoV-2 infection: a review of literature on autoimmune encephalitis in COVID-19
    Payus, Alvin Oliver
    Jeffree, Mohammad Saffree
    Ohn, May Honey
    Tan, Hui Jan
    Ibrahim, Azliza
    Chia, Yuen Kang
    Raymond, Azman Ali
    NEUROLOGICAL SCIENCES, 2022, 43 (03) : 1533 - 1547
  • [49] How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group
    Ferretti, Francesca
    Cannatelli, Rosanna
    Benucci, Maurizio
    Carmagnola, Stefania
    Clementi, Emilio
    Danelli, Piergiorgio
    Dilillo, Dario
    Fiorina, Paolo
    Galli, Massimo
    Gallieni, Maurizio
    Genovese, Giovanni
    Giorgi, Valeria
    Invernizzi, Alessandro
    Maconi, Giovanni
    Maier, Jeanette A.
    Marzano, Angelo V.
    Morpurgo, Paola S.
    Nebuloni, Manuela
    Radovanovic, Dejan
    Riva, Agostino
    Rizzardini, Giuliano
    Sabiu, Gianmarco
    Santus, Pierachille
    Staurenghi, Giovanni
    Zuccotti, Gianvincenzo
    Sarzi-Puttini, Pier Carlo
    Ardizzone, Sandro
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [50] Assessment of Neonatal Cord Blood SARS-CoV-2 Antibodies after COVID-19 Vaccination in Pregnancy: A Prospective Cohort Study
    Sourouni, Marina
    Braun, Janina
    Oelmeier, Kathrin
    Moellers, Mareike
    Willy, Daniela
    Hennies, Marc T.
    Koester, Helen Ann
    Pecks, Ulrich
    Klockenbusch, Walter
    Schmitz, Ralf
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (05) : 510 - 516